JARISLOWSKY FRASER Ltd Grows Stock Holdings in Haleon PLC Sponsored ADR $HLN

JARISLOWSKY FRASER Ltd lifted its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 12.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 821,006 shares of the company’s stock after acquiring an additional 90,904 shares during the quarter. JARISLOWSKY FRASER Ltd’s holdings in Haleon were worth $7,364,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of HLN. Bank of America Corp DE boosted its holdings in shares of Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares during the period. JPMorgan Chase & Co. raised its position in Haleon by 15.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,776,686 shares of the company’s stock valued at $91,014,000 after purchasing an additional 1,174,813 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Haleon by 6.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 7,857,196 shares of the company’s stock worth $81,479,000 after buying an additional 476,823 shares during the period. Acadian Asset Management LLC grew its position in shares of Haleon by 3,031.5% during the 2nd quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock worth $55,813,000 after buying an additional 5,212,711 shares in the last quarter. Finally, Raymond James Financial Inc. increased its stake in shares of Haleon by 0.7% during the second quarter. Raymond James Financial Inc. now owns 4,315,180 shares of the company’s stock valued at $44,748,000 after buying an additional 29,287 shares during the period. Institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 0.9%

NYSE HLN opened at $10.02 on Friday. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42. The company has a 50 day moving average price of $9.67 and a 200 day moving average price of $9.65. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The firm has a market cap of $44.60 billion, a PE ratio of 25.68 and a beta of 0.19.

Analyst Ratings Changes

Several research analysts have issued reports on HLN shares. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Barclays cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, September 16th. The Goldman Sachs Group upgraded shares of Haleon from a “neutral” rating to a “buy” rating in a research note on Wednesday, September 10th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.